NCT04238169

Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Xinqiao Hospital of Chongqing · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, multicenter, open-label study to observe the effect of SBRT and immunotherapy combined with Bevacizumab or not in stage IV non-squamous non-small cell lung cancer (NSCLC) with previously failed after chemotherapy.

Conditions

• Non-Small-Cell Lung Cancer Stage IV

Interventions

Type	Name	Description
DRUG	Bevacizumab	7.5mg/kg once every three weeks
DRUG	Toripalimab	240 mg once every three weeks
RADIATION	SBRT	30-50Gy/5F（2-4 lesions）

Timeline

• Start date: 2020-09-01
• Primary completion: 2022-12-31
• Completion: 2023-12-31
• First posted: 2020-01-23
• Last updated: 2024-02-28

Locations

1 site across 1 country: China